MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2018 International Congress

    Patient Experience of Parkinson’s Disease Psychosis Management

    P. Schmidt, F. Cubillos, A. Diaz, P. Wiener, S. Metz, N. Romero, A. Shim, D. Fredericks (Miami, FL, USA)

    Objective: To understand the experience and management of Parkinson’s disease psychosis (PDP). Background: PDP is a troubling non-motor symptom of Parkinson’s disease. Clinical approaches to…
  • 2018 International Congress

    Patterns of Long-Term Custodial Care in Parkinson Disease Psychosis

    J. Wetmore, H. Yan, M. Irfan, A. Shim, Y. Peng, D. Gilbertson, S. Li (Minneapolis, MN, USA)

    Objective: Parkinson Disease (PD) progression is frequently associated with development of psychosis (P), leading to significant morbidity, caregiver distress, and other consequences. Although PDP often…
  • 2018 International Congress

    Highly-selective blockade of 5-HT2A receptors with EMD-281,014 reduces the severity of L-DOPA-induced psychosis and dyskinesia in the MPTP-lesioned marmoset model of Parkinson’s disease

    A. Hamadjida, D. Bedard, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A) receptor EMD-281,014 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…
  • 2017 International Congress

    Predictors for psychosis in Huntington’s disease: preliminary analysis of the Enroll-HD database.

    N. Rocha, E. Furr-Stimming, A. Teixeira (Houston, TX, USA)

    Objective: To evaluate predictors for psychosis in HD. Background: Behavioral problems are present across all stages of HD, even preceding the development of the motor…
  • 2017 International Congress

    Parkinson Syndrome associated with inositol-1,4,5-triphosphate receptor antigen type 1 (ITPR1) antibodies

    B. Wimmer, K. Fuchs, U. Bogdahn, A. Heimeroth (Regensburg, Germany)

    Objective: To illustrate an unusual clinical presentation of Parkinson´s disease (PD) that was effectively treated with immune adsorption. Background: Autoimmune mediated movement disorders may be…
  • 2017 International Congress

    Chorea and psychosis as stroke presentation : report and brief review

    F. RADJI (AGEN, France)

    Objective: Describe phenomenology of rare movement disorders in stroke presentation and it pathophysiology Background: Acute movement disorders are a rare presentation of ischaemic stroke. hemichorea…
  • 2017 International Congress

    Late-Onset Wilson’s disease, Dementia, Ekbom syndrome and whitte matter hyperintensities

    F. Germiniani, P. Marques, F. Zorzetto, L. de Oliveira, H. Teive (Curitiba, Brazil)

    Objective: The aim of this study is to describe a patient with late-onset Wilson’s disease, dementia and Ekbom Syndrome. Background: Wilson's disease is an autosomal-recessive disorder…
  • 2017 International Congress

    The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset

    I. Frouni, S. Nuara, N. Veyres, C. Kwan, M.-J. Harraka, V. Nafade, L. Sid-Otmane, J. Gourdon, H. Adjia, P. Huot (Montreal, QC, Canada)

    Objective: To determine the effect of mirtazapine, a clinically-available anti-depressant, on psychosis and dyskinesia in Parkinson’s disease (PD). Background: Psychosis and dyskinesia cause significant morbidity…
  • 2017 International Congress

    The highly-selective metabotropic glutamate receptor 2 positive allosteric modulator LY-487,379 alleviates psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

    L. Sid-Otmane, S. Nuara, A. Hamadjida, N. Veyres, C. Rouillard, M. Panisset, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of metabotropic glutamate receptor 2 (mGluR2) activation on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced psychosis-like behaviours (PLBs) and dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset…
  • 2017 International Congress

    Capgras syndrome in advanced Parkinson disease

    C. Groth, A. Pusso, D. Huss, S. Sperling, B. Shah, M. Harrison, W.J. Elias, G.F. Wooten, M. Barrett (Charlottesville, VA, USA)

    Objective: The aims of this study were to investigate the frequency of Capgras syndrome in Parkinson's disease patients who have undergone Deep Brain Stimulation (DBS)…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley